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Cardiac Implantable Electronic Device (CIEDs) had been recommended as an integral part of heart failure 
management. Despite clear benefits on CIEDs itself, the rate of therapy penetration in Indonesia is still very low. 
Many contributing factors had been identified, they are lack of physician awareness, lack of referral, and 
mismatch between national insurance reimbursement and the cost of therapy. We focussed on talking about 
selective patient selection as one of the most feasible solutions to this problem.  
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 According to the European Society Cardiology Guidelines on 
Acute and Chronic Heart Failure in 2016, so far two CIEDs had been 
widely available in Indonesia. They are Cardiac Resynchronization 
Therapy (CRT) and Implantable Cardioverter Defibrillator (ICD).1 CRT 
works to synchronize the right and left ventricles movement, especially 
in the patients with the dilated left ventricle, low ejection fraction and 
showed the Left Bundle Branch Block (LBBB) pattern in their surface 
ECG.2 While ICD is clinically proven to reduce the risk of sudden 
cardiac death in heart failure patients with low ejection fraction.3
 Despite the clear evidence of its benefit and the huge number 
of our net indicated prevalence, the annual treatment rate of those 
devices are still very low in Indonesia. Data from Asia Pacific Heart 
Rhythm Society (APHRS) White Book revealed that there were only 62 
CRTs and 49 ICDs were implanted in all across Indonesia in 2018. 
Those numbers are very low compared to another growing country 
such as India, where in the same year they implanted almost 3.000   
CRTs and 4.000 ICDs. Many factors had been identified to contribute to 
those conditions, lack of centers, lack of reimbursement,  limited 
financial resources, lack of referral, lack of trained personnel, low 
awareness of guidelines and lack of operators. The magnitude of each 
problem is unknown, but according to APHRS White Book survey 
reimbursement and limited financial resources are the greatest obstacle 
for the physicians.
 The prospective funding of our national insurance grouped 
all the CIEDs implantation procedure, whether it was single chamber 
pacemaker, dual-chamber pacemaker, ICD, and CRT into one group of 
procedures with the same amount of reimbursement. In the case of ICD 
and CRT-P implantation, the reimbursement is far below the device 
unit price. Therefore, many cardiologists and cardiac electrophysiolo-
gists in Indonesia had to cope with this situation. Patient selection is a 
must to prioritize the patients who will get the most benefit from the 
treatment.
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Table 1. Total Number of CRT and ICD implanted in Indonesia
 2015
Total CRT Implanted / year
Total ICD Implanted / year  
67
24
2016
81
38
2017
63
45
2018
62
49
Note, CRT= Cardiac Resynchronization Therapy ; ICD= Implantable Cardioverter Defibrillator
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 In the case of CRT, we used to prioritize the patient who is predict-
ed to be a responder to therapy. CRT responder described as an improvement 
in clinical and echocardiography parameters. A decrease in LV end Systolic 
Volume (LVESV) ≥ 15 % and Increase in LV Ejection Fraction (LVEF) > 5 %.4  
According to the guidelines, class 1 recommendation for CRT is heart failure 
patients with ejection fraction less than 35%, LBBB ECG pattern with QRS 
duration of more than 120 msec.5 Other data told that there is a group of 
patients that were predicted to be more responsive to the therapy compared to 
another. Female compared to a male patient, non-ischemic cardiomyopathy 
compared to ischemic ones and Wider QRS compared to narrower QRS 
duration.6
 
 While in the case of ICD, the physician also performed a careful and 
very selective patient selection. For example, in Brugada syndrome, primary 
prevention of sudden cardiac death (SCD) with ICD is only performed to those 
with high risk. According to the only Indonesian National Registry, SCD is more 
likely in a patient with type 1 Brugada pattern and history of syncope. Addition-
al electrophysiology studies to assess the Right Ventricle Effective Refractory 
Periods (RV ERP) can be performed to get a better prediction.7 Despite primary 
prevention, the physician seems to be more prioritizing ICD as a secondary 
prevention treatment. From all of the procedures in the last 4 years, 75% of the 
procedures are secondary prevention.8
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Figure 1. National Insurance Reimbursement compared to CIEDs price
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